ReviewFrontiers in cell and developmental biology2026
Tumor-immune metabolic tug-of-war: from immune escape to targeting metabolic rewiring in cancer therapy.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of death worldwide, with nearly 20 million new cases and 9.7 million deaths reported in 2022. Projections estimate that annual incidence may increase to 35 million by 2050, underscoring cancer as both a biomedical challenge and a global socioeconomic burden. A key hallmark of malignancy that sustains this progression is metabolic reprogramming. Within the nutrient- and oxygen-deprived tumor microenvironment, cancer cells rewire their metabolism to generate the energy and biosynthetic intermediates necessary for unchecked proliferation, invasion, and metastasis. This metabolic adaptation, however, extends beyond tumor growth. By competing for critical nutrients such as glucose and glutamine, cancer cells establish a metabolic tug-of-war with immune cells, impairing their activation and antitumor functions. In addition, cancer cells produce oncometabolites that act as signaling molecules, fostering immune suppression. Together, nutrient competition and oncometabolite signaling contribute to immune evasion and therapeutic resistance. In this review, we examine the dynamic metabolic dialogue between tumors and the immune system, focusing on how cancer cells induce immune metabolic rewiring, how immune cells respond or succumb to these changes, and the therapeutic opportunities emerging from targeting metabolic vulnerabilities on both sides of the tug-of-war.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.